

## Remdesivir

S

### Lack of efficacy: case report

In a study report involving 11 patients, conducted from the review of medical charts of patients who were diagnosed with COVID-19 until February 2020, an 80-year-old man was described who exhibited lack of efficacy during treatment with remdesivir for COVID-19 [*not all routes stated and dosage not stated*].

The man had lymphoma. Hence, in January 2017, he received wedge resection. Additionally, he also had diabetes, renal insufficiency, asthma and squamous cell carcinoma of the lung. Moreover, he also had a history of smoking. Subsequently, for lymphoma, he had received rituximab from 22 February 2016–09 December 2020. Meanwhile, he developed COVID-19 hence, he was admitted. Subsequently, he developed secondary immunoglobulin deficiency. Therefore, from 11 December 2020–23 December 2020, he received treatment with off label intravenous immune-globulin [intravenous-immunoglobulin]. Concomitantly, he also received immunosuppressive therapy with unspecified steroids from 4 January 2021–06 January 2021; venetoclax, from 17 December 2020–26 December 2020 and ibrutinib from October 2020–December 2020. Thereafter, he received remdesivir. However, after 5 days from receiving remdesivir with decreasing cycle threshold values, he developed acute respiratory failure which eventually led to his death. Hence a lack of efficacy was reported for remdesivir.

Rufenacht S, et al. Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series. *Infection* 50: 783-790, No. 3, Jun 2022.

Available from: URL: <http://doi.org/10.1007/s15010-022-01821-y>

803675471